Skip to main content
. 2015 Aug 14;94(32):e1341. doi: 10.1097/MD.0000000000001341

FIGURE 2.

FIGURE 2

Cumulative rates of VR and CR after cessation of nucleos(t)ide analogues in patients with chronic hepatitis B and achieving APASL treatment endpoint. (A) VR and CR rates in HBeAg-positive patients. (B) VR and CR rates in HBeAg-negative patients. CR = clinical relapse, VR = virological relapse.